- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00963989
Imaging Guided Patient Selection for Interventional Revascularization Therapy (START)
The START Trial: Clinical Outcome in Acute Stroke Treatment After Imaging Guided Patient Selection for Interventional Revascularization Therapy
Study Overview
Detailed Description
Study Title: The START Trial: Clinical Outcome in Acute Stroke Treatment after Imaging Guided Patient Selection for Interventional Revascularization Therapy
Study Objective: The objective of this clinical evaluation is to determine the safety and effectiveness of the Penumbra System in a stroke cohort who presents within 8 hours from symptom onset and with a known core infarct volume at admission. The data will also be used to determine if there is a correlation between infarct volume and functional outcome at 90 days post-procedure. Safety is defined by the procedural serious adverse events, and effectiveness is defined by the rate of revascularization (TIMI 2-3/TICI 2a-3) and good functional outcome. Good functional outcome is defined by a modified Rankin scale (mRS) score of 2 or less at 90 days post-procedure. Core infarct volume at admission will be assessed by computed tomography perfusion (CTP), computed tomography angiography (CTA) or magnetic resonance DWI scans. The core infarct volumes will be sub-grouped by <50cc, 50-100cc and >100cc to determine the correlation with patient functional outcome.
Study Design: A prospective, single arm, multi-center trial. Up to 200 patients at up to 45 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis.
Patient Population: Patients presenting with symptoms of acute ischemic stroke within 8 hours from symptom onset and with a known imaging-defined infarct volume will be enrolled for interventional treatment by the Penumbra System to achieve revascularization of the target vessel territory.
Indication: The Penumbra System is intended for use in the revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (within the internal carotid, middle cerebral - M1 and M2 segments, basilar, and vertebral arteries) within 8 hours of symptom onset.
Sample Size Justification: Up to 200 subjects will be enrolled in order to obtain up to 150 evaluable patients. Assuming a post-procedure angiographic success (TIMI 2-3/TICI 2a-3) rate of 80% (120/150), the expected two-sided exact binomial 95% confidence interval is (72.7%, 86.1%). Assuming a 90-day mRS success (mRS 0-2) rate of 30%, the expected two-sided exact binomial 95% confidence interval is (22.8%, 38.0%). Additionally, the study results will be used for sample size estimates for a potential future randomized, concurrent controlled trial.
Core Laboratory and Clinical Event Committee An independent Core Lab will review and score all imaging scans for infarct volume, TIMI, TICI and ICH. A Clinical Event Committee will adjudicate all Serious Adverse Events for severity and causality (disease-, procedure-, drug-, or device-relatedness.
Study Rationale: Use of interventional revascularization techniques offer several potential clinical benefits by improving cerebral perfusion to the target vascular territory in certain patients. The validation of a simple, pragmatic, and executable image guided patient selection paradigm may identify a cohort of acute stroke patients who will benefit from interventional treatment by the Penumbra System and in whom revascularization as a treatment for acute stroke will be indicated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- From 18 to 85 years of age.
- Evidence of proximal anterior circulation large vessel occlusion (TIMI /TICI 0-1) (Tables 2A & B). Target vessel occlusion may include the supra-clinoid segment of the ICA through the M1 segment of the MCA.
- Presented with symptoms consistent with acute ischemic stroke within 8 hours of symptom onset. Patients who presented within 3 hours must be ineligible or refractory to IV rtPA therapy.
- At time of enrollment, neurological deficit resulting in an NIH Stroke Scale (NIHSS) score of 10 or greater.
- Core infarct volume assessed by CTP, CTA or DWI scans within 60 minutes to arterial puncture.
- Signed informed consent.
Exclusion Criteria:
- History of stroke in the past 3 months.
- Vessel tortuosity too difficult to allow endovascular access.
- Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score of 1 or greater.
- Known severe allergy to contrast media.
- Uncontrolled hypertension (defined as systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg).
Noncontrast CT evidence of the following conditions before enrollment:
- Significant mass effect with midline shift;
- Evidence of intracranial hemorrhage.
- Angiographic evidence of an arterial stenosis proximal to the occlusion that could prevent thrombus removal.
- Angiographic evidence of preexisting arterial injury.
- Life expectancy less than 90 days.
- Participation in another clinical investigation that could confound the evaluation of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Penumbra Device Arm
|
The Penumbra System is used to revascularize clotted cerebral blood vessels.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Functional Outcome as Defined by a mRS of 0-2 at 90 Days Post-procedure
Time Frame: At 90 days post-procedure
|
Modified Rankin Scale (mRS) ranges from 0 to 5, with higher scores being worse.
|
At 90 days post-procedure
|
Angiographic Assessment of Vessel Patency as Measured by TIMI Score
Time Frame: At immediate post-procedure
|
Defined by Number of participants with Thrombolysis in Myocardial Infarction (TIMI) 2-3. A lower score means a worse outcome and higher scores means better outcome on a scale of 0-3. |
At immediate post-procedure
|
Angiographic Assessment of Vessel Patency as Measured by Modified TICI Score
Time Frame: At immediate post-procedure
|
Defined by number of participants with modified thrombolysis in cerebral infarction (TICI) 2-3. A lower score means a worse outcome and higher scores means better outcome on a scale of 0-3. |
At immediate post-procedure
|
Procedural Serious Adverse Events During the Procedure
Time Frame: During the procedure, approximately 24 hours
|
Defined by serious adverse events (SAEs) within 24 hours of the procedure
|
During the procedure, approximately 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Good Neurological Recovery Post-procedure as Defined by a 10 Points or More Improvement on the NIHSS at Discharge
Time Frame: At Discharge, an average of 7 days
|
At Discharge, an average of 7 days
|
Incidence of Symptomatic and Asymptomatic Hemorrhage Based on the ECASS Criteria and Patient Neurological Status Within 24 Hours of the Procedure
Time Frame: Within 24 hours of the procedure
|
Within 24 hours of the procedure
|
All Cause Mortality at 90 Days Post-procedure
Time Frame: At 90 days post-procedure
|
At 90 days post-procedure
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP 2480.A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Ischemic Stroke
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Dongzhimen Hospital, BeijingThe Second Hospital of Hebei Medical University; Peking University Third Hospital and other collaboratorsRecruitingStroke, Ischemic | Stroke, Acute | Acute Ischemic StrokeChina
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
University of MiamiTemporarily not availableStroke, Ischemic | Stroke, Acute | Mesenchymal Stem Cells | Acute Ischemic Stroke | Stroke/Brain AttackUnited States
-
The University of Texas Health Science Center,...National Center for Advancing Translational Sciences (NCATS)CompletedAcute Ischemic Stroke (AIS)United States
-
Shanghai Yueyang Integrated Medicine HospitalRecruitingIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalCompletedIschemic Stroke, AcuteChina
-
Beijing Tiantan HospitalRecruitingIschemic Stroke, AcuteChina
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; New York Presbyterian HospitalCompletedCancer Patients First-ever Acute Ischemic StrokeUnited States
Clinical Trials on Penumbra System
-
Penumbra Inc.CompletedAcute Ischemic Stroke From Large Vessel OcclusionUnited States
-
Penumbra Inc.Terminated
-
Penumbra Inc.CompletedStroke, IschemicUnited States, Spain, Germany, France, Poland, Russian Federation
-
Penumbra Inc.Completed
-
Penumbra Inc.Completed
-
Penumbra Inc.WithdrawnArteriovenous Malformations | Visceral Artery AneurysmsUnited States
-
Penumbra Inc.CompletedIntracranial AneurysmUnited States, Canada
-
Penumbra Inc.RecruitingAcute Ischemic Stroke | Large Vessel OcclusionUnited States
-
Abington Memorial HospitalSuspendedIschemic StrokeUnited States